We will not necessarily know anything by late January. Even if no deals happen by then and they propose to vote on authorizing more shares at the late March meeting, anything can happen by end of March. Including data and/or deals. Actually, they will definitely propose to authorize new shares no matter what happens because a clinical biotech must always have them available.
News 
Market Data 
Discover 
AI
